---
title: "Vonaprument (ANX007) in Geographic atrophy secondary to age-related macular degeneration: Place in treatment, anticipated use, and care setting"
description: "Formulary evidence on Vonaprument (ANX007) in Geographic atrophy secondary to age-related macular degeneration: Place in treatment, anticipated use, and care setting. Topics: Summary: anticipated use and care setting; Investigational dose, frequency, and route; Provider and setting for intravitreal treatment of AMD; Referral to retina specialists and office visit frequency for approved complement inhibitors; 2 further topics. 6 evidence topics quoted from 5 sources."
canonical: "https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/product-information-and-disease-description/place-in-treatment-anticipated-use-and-care-setting"
published: "2026-11-15T20:23:59-05:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Vonaprument (ANX007) in Geographic atrophy secondary to age-related macular degeneration: Place in treatment, anticipated use, and care setting

<a id="heading-2.2.2.2"></a>

## 2.2.2.2 Place in Treatment, Anticipated Use, and Care Setting

<a id="topic-2.2.2.2-1"></a>

### Summary: anticipated use and care setting

Vonaprument is not approved for any use. In the phase 3 ARCHER II trial it is given as 5.0 mg per eye by monthly intravitreal injection, which places its anticipated use among physician-administered intravitreal therapies, the same route and setting as the two approved complement inhibitors for geographic atrophy, pegcetacoplan and avacincaptad pegol. The AAO Preferred Practice Pattern states that the ophthalmologist should administer all treatment and anti-VEGF injections for AMD. A U.S. expert panel recommends nonurgent referral to a retina specialist for any suspected geographic atrophy and notes that current anti-complement therapy requires “office visits every 1 to 2 months”.

In a footnote that begins “Based on market reports”, the sponsor estimates that approximately 75,000 U.S. patients are actively treated with available therapies, about 10% of the 800,000 people diagnosed with geographic atrophy or under the care of retina specialists and about 5% of an estimated 1.5 million U.S. people with geographic atrophy. Medicare Part B fee-for-service data for 2025 record 32,021 beneficiaries with 168,366 claims for pegcetacoplan and 27,497 beneficiaries with 140,741 claims for avacincaptad pegol, with total spending of about $451.1 million and $364.9 million. For the first quarter of 2026 the counts were 24,179 and 23,315 beneficiaries. No source states a planned price, distribution model, or position in a treatment sequence for vonaprument.

Source: [Annexon Biosciences investor event presentation (2026)](https://ir.annexonbio.com/static-files/e55e4d2a-22d8-43a8-bf8c-6449df3a261b); [Annexon Biosciences ARCHER II expansion press release (2026)](https://ir.annexonbio.com/news-releases/news-release-details/annexon-expands-vonaprument-phase-3-program-geographic-atrophy); [Vemulakonda et al. (2025)](https://www.aao.org/Assets/f832e5ac-c047-4d1c-bdab-c5e52173623d/638760137410500000/age-related-macular-degeneration-ppp-pdf); [Regillo et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10850989/); [CMS Medicare Quarterly Part B Spending by Drug (2026)](https://data.cms.gov/data-api/v1/dataset/bf6a5b3b-31ee-4abb-b1ad-2607a1e7510a/data?filter%5Bc%5D%5Bcondition%5D%5Bpath%5D=HCPCS_Cd&filter%5Bc%5D%5Bcondition%5D%5Boperator%5D=IN&filter%5Bc%5D%5Bcondition%5D%5Bvalue%5D%5B%5D=J2781&filter%5Bc%5D%5Bcondition%5D%5Bvalue%5D%5B%5D=J2782)

<a id="topic-2.2.2.2-2"></a>

### Investigational dose, frequency, and route

> “Vonaprument (ANX007) Monthly 5.0 mg/eye”
> “25 microliter dose”

Source: [Annexon Biosciences investor event presentation (2026)](https://ir.annexonbio.com/static-files/e55e4d2a-22d8-43a8-bf8c-6449df3a261b)

> “It is formulated for intravitreal (IVT) administration, with the potential to be the first targeted vision-preserving therapy for GA.”

Source: [Annexon Biosciences ARCHER II expansion press release (2026)](https://ir.annexonbio.com/news-releases/news-release-details/annexon-expands-vonaprument-phase-3-program-geographic-atrophy)

<a id="topic-2.2.2.2-3"></a>

### Provider and setting for intravitreal treatment of AMD

> “The ophthalmologist should perform the examination, order appropriate testing, and administer all treatment and anti-VEGF injections”

Source: [Vemulakonda et al. (2025)](https://www.aao.org/Assets/f832e5ac-c047-4d1c-bdab-c5e52173623d/638760137410500000/age-related-macular-degeneration-ppp-pdf)

<a id="topic-2.2.2.2-4"></a>

### Referral to retina specialists and office visit frequency for approved complement inhibitors

> “A nonurgent referral to a retina specialist is recommended for any suspected GA in one or both eyes, whereas a more urgent referral should be made for any patient with suspected neovascular AMD (nAMD)”
> “To streamline care, patients may consider monitoring (or possibly even treatment) by their comprehensive ophthalmologist under the guidance of a retina specialist, which may help maintain compliance and overall treatment fidelity.”
> “Current anti-complement therapy for GA requires treatment with office visits every 1 to 2 months.”
> “Timing of referral to retina specialists must be optimized to consider the burden on patients and caregivers.”

Source: [Regillo et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10850989/)

<a id="topic-2.2.2.2-5"></a>

### Sponsor estimate of the treated and untreated U.S. population

> “Based on market reports, approximately 75,000 patients are being actively treated with available therapies in the US, representing ~10% of the 800,000 people diagnosed with GA/under the care of retina specialists, but only about 5% of the 1.5M US population with GA”
> “of US patients being treated today”

Source: [Annexon Biosciences investor event presentation (2026)](https://ir.annexonbio.com/static-files/e55e4d2a-22d8-43a8-bf8c-6449df3a261b)

<a id="topic-2.2.2.2-6"></a>

### Medicare Part B use of approved complement inhibitors for geographic atrophy

| Brand name | HCPCS description | Period | Beneficiaries | Claims | Total spending (USD) |
| --- | --- | --- | --- | --- | --- |
| “SYFOVRE” | “INJ, PEGCETACOPLAN, 1MG” | “2025 (Q1-Q4)” | “32021” | “168366” | “451069360.05” |
| “SYFOVRE” | “INJ, PEGCETACOPLAN, 1MG” | “2026 (Q1)” | “24179” | “41654” | “109568082.68” |
| “IZERVAY” | “INJ AVACINCAPTAD PEGOL 0.1MG” | “2025 (Q1-Q4)” | “27497” | “140741” | “364934587.1” |
| “IZERVAY” | “INJ AVACINCAPTAD PEGOL 0.1MG” | “2026 (Q1)” | “23315” | “41264” | “105232261.84” |

Source: [CMS Medicare Quarterly Part B Spending by Drug (2026)](https://data.cms.gov/data-api/v1/dataset/bf6a5b3b-31ee-4abb-b1ad-2607a1e7510a/data?filter%5Bc%5D%5Bcondition%5D%5Bpath%5D=HCPCS_Cd&filter%5Bc%5D%5Bcondition%5D%5Boperator%5D=IN&filter%5Bc%5D%5Bcondition%5D%5Bvalue%5D%5B%5D=J2781&filter%5Bc%5D%5Bcondition%5D%5Bvalue%5D%5B%5D=J2782)

## Related pages
- [Vonaprument (ANX007): Geographic atrophy secondary to age-related macular degeneration](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration) · [Markdown](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration.md)
- [Vonaprument (ANX007) in Geographic atrophy secondary to age-related macular degeneration: Terms and abbreviations](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/terms-and-abbreviations.md)
- [Vonaprument (ANX007): Geographic atrophy secondary to age-related macular degeneration](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/executive-summary) · [Markdown](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/executive-summary.md)
- [Vonaprument (ANX007) in Geographic atrophy secondary to age-related macular degeneration: Product information and disease description](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/product-information-and-disease-description.md)
- [Vonaprument (ANX007) in Geographic atrophy secondary to age-related macular degeneration: Clinical evidence](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/clinical-evidence.md)
- [Vonaprument (ANX007) in Geographic atrophy secondary to age-related macular degeneration: Economic information and modeling report](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/economics) · [Markdown](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/economics.md)
- [Vonaprument (ANX007) in Geographic atrophy secondary to age-related macular degeneration: References](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/references) · [Markdown](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/references.md)
